--------------------------------------------------------------------------------

Exhibit 10.1

Summary of 2008 Named Executive Officer Cash Compensation

The Compensation Committee of our Board of Directors has approved 2008 base
salaries for our named executive officers as set forth below.

The Compensation Committee has also approved a process for the determination of
2008 cash bonuses for our named executive officers, pursuant to which bonuses
will be determined in the discretion of the Compensation Committee based on the
achievement of certain corporate and individual goals in 2008.  The corporate
goals include objectives relating to the development of drug candidates and the
achievement of specified financial targets.  The achievement of these goals will
be evaluated by the Compensation Committee in making determinations regarding
bonuses for 2008 performance.  The Compensation Committee has established a
bonus target, expressed as a percentage of base salary, for each of our named
executive officers, assuming that corporate and individual goals are fully
achieved.  The bonus target percentage for each of our named executive officers
is set forth below.

Name and Position
 
2008
Base Salary
   
2008
Bonus Target
 
Arthur T. Sands, M.D., Ph.D.
President and Chief Executive Officer
  $ 560,000       50 %
Julia P. Gregory
Executive Vice President and Chief Financial Officer
  $ 350,000       35 %
Alan J. Main, Ph.D.
Executive Vice President of Pharmaceutical Research
  $ 340,000       35 %
Jeffrey L. Wade, J.D.
Executive Vice President and General Counsel
  $ 340,000       35 %
Brian P. Zambrowicz, Ph.D.
Executive Vice President and Chief Scientific Officer
  $ 365,000       40 %

 
 

--------------------------------------------------------------------------------